// App-Quantinova.ai

e19397 : Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma (CSCC): A cost-effectiveness analysis.

Researchers

Presenter

  • Eleanor Paul

Principal Investigators

  • Andreas Kuznik

  • Sam Keeping

  • Chieh-I Chen

  • Medha Sasane

  • Yingxin Xu

  • Gerasimos Konidaris

  • Kokuvi Atsou

  • Dieter Ayers

  • Emily S Ruiz

  • Nikhil I. Khushalani

  • Shannon Cope

Medical Centers

  • Precision Xtract, Vancouver, BC, Canada

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Sanofi, Bridgewater, NJ

  • INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, Sorbonne Universités, France

  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

  • Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL

Locations

  • Canada

  • United States

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Erbitux

  • Erlotinib hydrochloride

  • gefitinib

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved